Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- And chronic kidney disease-associated cachexia

Xinxia Zhu, Michael F. Callahan, Kenneth A. Gruber, Marek Szumowski, Daniel L. Marks

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Cachexia, a devastating wasting syndrome characterized by severe weight loss with specific losses of muscle and adipose tissue, is driven by reduced food intake, increased energy expenditure, excess catabolism, and inflammation. Cachexia is associated with poor prognosis and high mortality and frequently occurs in patients with cancer, chronic kidney disease, infection, and many other illnesses. There is no effective treatment for this condition. Hypothalamic melanocortins have a potent and long-lasting inhibitory effect on feeding and anabolism, and pathophysiological processes increase melanocortin signaling tone, leading to anorexia, metabolic changes, and eventual cachexia. We used 3 rat models of anorexia and cachexia (LPS, methylcholanthrene sarcoma, and 5/6 subtotal nephrectomy) to evaluate efficacy of TCMCB07, a synthetic antagonist of the melanocortin-4 receptor. Our data show that peripheral treatment using TCMCB07 with intraperitoneal, subcutaneous, and oral administration increased food intake and body weight and preserved fat mass and lean mass during cachexia and LPS-induced anorexia. Furthermore, administration of TCMCB07 diminished hypothalamic inflammatory gene expression in cancer cachexia. These results suggest that peripheral TCMCB07 treatment effectively inhibits central melanocortin signaling and therefore stimulates appetite and enhances anabolism, indicating that TCMCB07 is a promising drug candidate for treating cachexia.

Original languageEnglish (US)
Pages (from-to)4921-4934
Number of pages14
JournalJournal of Clinical Investigation
Volume130
Issue number9
DOIs
StatePublished - Sep 1 2020

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- And chronic kidney disease-associated cachexia'. Together they form a unique fingerprint.

Cite this